Prices are updated after-hours

Glass Nasdaq

Aileron Therapeutics, Inc.

ALRN | $4.93 3.79% 2.66% 100K

(0.0% 1d) (-13.5% 1m) (246.0% 1y) (0.0% 2d) (3.8% 3d) (4.0% 7d) (51.0% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 83,674,484
http://www.aileronrx.com
Sec Filling | Patents | 13 employees

Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead products candidate, ALRN-6924 which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky in June 2005 and is headquartered in Cambridge, MA.

cancer glass t-cell nash treatment ceiling

add to watch list Paper trade email alert is off

Airgain, Inc.

AIRG 4 | $5.62 0.9% 0.89% 6.9K

Electronic Technology

(0.0% 1d) (3.3% 1m) (-3.1% 1y) (0.0% 2d) (0.9% 3d) (6.2% 7d) (-40.31% volume)
Earnings Calendar: 2024-03-06
Market Cap: $ 59,035,835
http://www.airgain.com
Sec Filling | Patents | 126 employees

(US) Airgain, Inc. provides embedded antenna products, integration support and test services. The firm works in partnership with the entire ecosystem, including carriers, chipset suppliers, OEMs, and ODMs. Its products include embedded, external and carrier-class antennas. The company offers custom antenna design and performance validation services. Its antennas are deployed in carrier, fleet, enterprise, residential, private, government, and public safety wireless networks and systems, including set-top boxes, access points, routers, modems, gateways, media adapters, and asset tracking devices. The company was founded in 1995 and is headquartered in San Diego, CA.

glass

add to watch list Paper trade email alert is off

Alnylam Pharmaceuticals, Inc.

ALNY | $143.8 -1.55% -1.58% 400K

Health Technology

(0.0% 1d) (-5.4% 1m) (-27.2% 1y) (0.0% 2d) (-1.6% 3d) (-0.4% 7d) (-27.29% volume)
Earnings Calendar: 2024-02-15
Market Cap: $ 18,111,005,033
http://www.alnylam.com
Sec Filling | Patents | 1323 employees

(US) Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

glass genetic msa treatment

Drugs

GIVLAARI (givosiran sodium)
Onpattro (patisiran)
OXLUMO (lumasiran)

add to watch list Paper trade email alert is off

Apogee Enterprises, Inc.

APOG F | $62.26 1.01% 1.02% 190K

Producer Manufacturing

(0.0% 1d) (6.1% 1m) (49.9% 1y) (0.0% 2d) (1.0% 3d) (7.4% 7d) (-38.97% volume)
Earnings Calendar: 2023-12-21
Market Cap: $ 1,375,018,201
http://www.apog.com
Sec Filling | Patents | 7200 employees

Apogee Enterprises, Inc. engages in the design and development of architectural products and services. It also provides architectural glass, aluminum framing systems and installation services for buildings, as well as value-added glazing products for custom picture framing. The company operates through the following segments: Architectural Framing Systems, Architectural Glass, Architectural Services, and Large-Scale Optical Technologies. The Architectural Framing Systems segment designs, engineers, fabricates and finishes aluminum window, curtainwall, storefront and entrance systems comprising the exterior of buildings. The Architectural Glass segment fabricates coated, high-performance glass used in custom window and wall systems. The Architectural Services segment integrates technical services, project management, and field installation services to design, engineer, fabricate, and install building glass and curtainwall systems. The Large-Scale Optical Technologies (LSO) segment manufactures value-added coated glass and acrylic products for custom framing, museum, and technical glass markets. Apogee Enterprises was founded in 1949 and is headquartered in Minneapolis, MN.

optical glass

add to watch list Paper trade email alert is off

aTyr Pharma, Inc.

LIFE | $1.6 -1.23% -1.57% 290K

Health Technology

(0.0% 1d) (-16.4% 1m) (-20.8% 1y) (0.0% 2d) (-1.2% 3d) (0.0% 7d) (20.86% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 108,705,346
http://www.atyrpharma.com
Sec Filling | Patents | 44 employees

(US) aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. It operates in a single accounting segment. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

glass diagnostics

add to watch list Paper trade email alert is off

Auburn National Bancorporation, Inc.

AUBN | $17.17 0.12% 1.34% 1.4K

Finance

(0.0% 1d) (-11.2% 1m) (-25.3% 1y) (0.0% 2d) (0.2% 3d) (2.5% 7d) (61.54% volume)
Earnings Calendar:
Market Cap: $ 59,986,383
http://www.auburnbank.com
Sec Filling | Patents | 164 employees

Auburn National Bancorporation, Inc. is a bank holding company. It engages in the provision of banking services to commercial and retail customers. The company operates through the following segments: commercial and industrial; construction and land development; commercial real estate; residential real estate and consumer installment. The Commercial and industrial segment includes loans to finance business operations, equipment purchases, or other needs for small and medium-sized commercial customers. The Construction and land development segment includes both loans and credit lines for the purpose of purchasing, carrying and developing land into commercial developments or residential subdivisions. The Commercial and industrial segment includes loans disaggregated into three classes: owner occupied, multi-family and other. The Residential real estate segment includes consumer mortgage and investment property. The Consumer installment segment includes loans to individuals both secured by personal property and unsecured. The company was founded in 1990 and is headquartered in Auburn, AL.

security glass als construction

add to watch list Paper trade email alert is off

Bicycle Therapeutics plc

BCYC | $22.67 -0.04% 0.09% 520K

Health Technology

(0.0% 1d) (-7.6% 1m) (13.4% 1y) (0.0% 2d) (-0.0% 3d) (-3.3% 7d) (216.95% volume)
Earnings Calendar:
Market Cap: $ 482,979,839
http://www.bicycletherapeutics.com
Sec Filling | Patents | 72 employees

(United Kingdom) Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

glass

add to watch list Paper trade email alert is off

Brookline Bancorp, Inc.

BRKL | $9.54 -0.21% -0.26% 290K

Finance

(0.0% 1d) (1.1% 1m) (-3.4% 1y) (0.0% 2d) (-0.2% 3d) (1.7% 7d) (-3.77% volume)
Earnings Calendar: 2024-01-24
Market Cap: $ 855,220,188
http://www.brooklinebancorp.com
Sec Filling | Patents | 811 employees

Brookline Bancorp, Inc. operates as a bank holding company. It operates through the following segments: commercial real estate loans, commercial loans and leases and consumer loans. The Commercial real estate loans segment is divided into three classes: commercial real estate mortgage loans, multi-family mortgage loans and construction loans. The Commercial loans and leases segment is divided into three classes: commercial loans which include taxi medallion loans, equipment financing and loans to condominium associations. The Consumer loans segment is divided into three classes: residential mortgage loans, home equity loans and other consumer loans. The company was founded in November 1997 and is headquartered in Boston, MA.

glass msa construction

add to watch list Paper trade email alert is off

C4 Therapeutics, Inc.

CCCC | $6.47 -6.23% -6.65% 740K

Health Technology

(0.0% 1d) (-18.5% 1m) (112.1% 1y) (0.0% 2d) (-6.2% 3d) (-3.7% 7d) (14.03% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 443,846,328
http://www.c4therapeutics.com
Sec Filling | Patents | 99 employees

C4 Therapeutics, Inc. provides new class of targeted protein degradation. It develops Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Cambridge, MA.

glass t-cell ceiling

add to watch list Paper trade email alert is off

CIM Commercial Trust Corporation

CMCT 4 | $3.4993 2.62% 3.47% 420

Finance

(0.0% 1d) (-16.3% 1m) (-22.9% 1y) (0.0% 2d) (2.6% 3d) (3.2% 7d) (-95.62% volume)
Earnings Calendar: 2024-04-01
Market Cap: $ 79,737,643
http://www.cimcommercial.com
Sec Filling | Patents | 5 employees

(US) CIM Commercial Trust Corp. engages in the acquisition, ownership, and operation of Class A and office assets. It operates through the following segments: Office, Hotel, Multifamily, and Lending. The Office segment consists of rental of office space and other tenant services, including tenant reimbursements, parking, and storage space rental. The Hotel segment relates to operations of hotel properties and rental income generated from a garage located directly across the street from one of the hotels. The Multifamily segment refers to rental of apartments and other tenant services. The Lending segment includes income from the yield and other related fee income earned on its loans receivable. The company was founded in 1979 and is headquartered in Dallas, TX.

acquisitions hotel glass

add to watch list Paper trade email alert is off

CME Group Inc.

CME | $212.59 -1.93% -1.93% 2.2M

Finance

(0.0% 1d) (-0.1% 1m) (15.0% 1y) (0.0% 2d) (-1.9% 3d) (-0.2% 7d) (28.71% volume)
Earnings Calendar: 2024-02-14
Market Cap: $ 76,537,760,882
http://www.cmegroup.com
Sec Filling | Patents | 4360 employees

(US) CME Group, Inc. operates as a security and commodity exchange company. It provides the risk management and investment needs of customers around the globe. The firm offers products across various asset classes based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, metals, weather and real estate. It brings buyers and sellers together through its CME Globex electronic trading platform across the globe and its open outcry trading facilities in Chicago and New York City. The firm also provides clearing and settlement services for exchange-traded contracts, as well as for cleared over-the-counter derivatives transactions. It also offers market data services-including live quotes, delayed quotes, market reports and a comprehensive historical data service and has expanded into the index services business through CME Group Index Services. The company was founded in 1898 and is headquartered in Chicago, IL.

energy security electronics glass agricultural msa agriculture

add to watch list Paper trade email alert is off

Foghorn Therapeutics Inc.

FHTX | $5.21 0.97% 0.96% 110K

Health Technology

(0.0% 1d) (-14.2% 1m) (-21.7% 1y) (0.0% 2d) (1.0% 3d) (-1.7% 7d) (143.3% volume)
Earnings Calendar: 2022-11-08
Market Cap: $ 221,768,360
http://www.foghorntx.com
Sec Filling | Patents | 85 employees

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.

glass msa

add to watch list Paper trade email alert is off

Generation Bio Co.

GBIO | News | $2.99 -8.28% -8.85% 110K

Health Technology

(0.0% 1d) (-5.7% 1m) (-34.9% 1y) (0.0% 2d) (-8.3% 3d) (6.8% 7d) (-46.49% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 198,766,562
http://www.generationbio.com
Sec Filling | Patents | 85 employees

Generation Bio Co. is a genetic medicines company focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA; a novel cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.

gene therapies glass t-cell genetic treatment ceiling construction

add to watch list Paper trade email alert is off

Genprex, Inc.

GNPX | $2.21 -4.33% 6.77% 20K

Health Technology

(0.0% 1d) (-19.3% 1m) (176.3% 1y) (0.0% 2d) (-4.3% 3d) (3.8% 7d) (-35.06% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 4,222,075
http://www.genprex.com
Sec Filling | Patents | 8 employees

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company's lead product candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca's Tagrisso®) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. The company was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.

cancer lung cancer gene therapies diabetes diabetic glass food t-cell lungs treatment msa ceiling

add to watch list Paper trade email alert is off

Gentex Corporation

GNTX | $35.16 1.44% 1.39% 1.4M

Producer Manufacturing

(0.0% 1d) (-2.1% 1m) (33.8% 1y) (0.0% 2d) (1.4% 3d) (3.7% 7d) (36.65% volume)
Earnings Calendar: 2023-10-27
Market Cap: $ 8,133,235,390
http://www.gentex.com
Sec Filling | Patents | 5874 employees

(US) Gentex Corp. engages in the design, development, and manufacture and supply of digital vision, connected car, dimmable glass, and fire protection products, Its revenue is derived from the production and sales of automotive products in the United States, Germany, and Japan. Its products include automatic-dimming rearview mirrors, dimmable aircraft windows, and commercial smoke alarms and signaling devices. The company was founded by Fred Bauer in 1974 and is headquartered in Zeeland, MI.

glass automotive

add to watch list Paper trade email alert is off

Greenlane Holdings, Inc.

GNLN | $0.5517 -8.05% -9.03% 370K

Distribution Services

(0.0% 1d) (0.9% 1m) (-81.5% 1y) (0.0% 2d) (-8.3% 3d) (-12.7% 7d) (25.36% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 2,060,164
http://www.gnln.com
Sec Filling | Patents | 350 employees

(US) Greenlane Holdings, Inc. distributes and supplies vaporization products and accessories for vape shops and dispensaries. The firm offers packaging, rolling papers, grinders, glass products, and smoking accessories. The company was founded by Aaron LoCascio and Adam Schoenfeld in 2005 and is headquartered in Boca Raton, FL.

glass

add to watch list Paper trade email alert is off

Harpoon Therapeutics, Inc.

HARP | $23.01 0.07% 6.6M

Health Technology

(0.0% 1d) (0.0% 1m) (3909.4% 1y) (0.0% 2d) (0.1% 3d) (0.0% 7d) (122.25% volume)
Earnings Calendar: 2024-03-13
Market Cap: $ 389,611,579
http://www.harpoontx.com
Sec Filling | Patents | 61 employees

(US) Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which develops a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTACs) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.

cancer immunotherapy glass t-cell treatment ceiling construction

add to watch list Paper trade email alert is off

IMV Inc.

IMV | $0.8225 -2.74% 45K

Health Technology

(0.0% 1d) (0.0% 1m) (-2.5% 1y) (-2.5% 2d) (-2.5% 3d) (0.0% 7d) (-76.64% volume)
Earnings Calendar: 2023-05-12
Market Cap: $ 9,632,821
http://www.imv-inc.com
Sec Filling | Patents | n/a employees

IMV, Inc. is a clinical-stage biopharmaceutical company that engages in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company leverages its delivery platform (DPX) that programs immune cells directly within the human body to produce robust and sustained target killing capabilities. Its drug candidate, DPX-Survivac, is a targeted T cell therapy that has completed multiple phases 1 and 1b trials generating results in late-stage ovarian cancer and relapsed/refractory DLBCL (Diffuse Large B Cell Lymphoma) where it has identified a predictive biomarker. The company was founded by Warwick Kimmins and Brian E. Lowe on May 18, 2007 and is headquartered in Dartmouth, Canada.

vaccine covid cancer ovarian cancer immunotherapy infectious disease glass t-cell ceiling

add to watch list Paper trade email alert is off

Integrated Media Technology Limited

IMTE | $1.975 10.96% -18.02% 7.1K

Electronic Technology

(0.0% 1d) (-14.3% 1m) (457.6% 1y) (0.0% 2d) (11.2% 3d) (26.9% 7d) (305.68% volume)
Earnings Calendar:
Market Cap: $ 40,858,419
http://www.imtechltd.com
Sec Filling | Patents | 53 employees

Integrated Media Technology Ltd. engages in developing, manufacturing and distributing of 3-dimension display equipment and wholesales audio products. It focuses on the business activities in the sale and distribution of autostereoscopic 3D display, 3D conversion equipment and software, development and sale of 3D autostereoscopic technology and provision of 3D consultancy services. The firm’s products include Glasses-free 3D Video Wall, Glasses-free 4K 3D Display, 4K3DPro Super Workstation, Visumotion, Glasses-free 3D Mobile Devices and MemtoTM Picture Frames. The company was founded on Augest 8, 2008 and is headquartered in Adelaide, Australia.

audio glass 3d

add to watch list Paper trade email alert is off

Intellia Therapeutics, Inc.

NTLA | $21.17 -1.67% -1.75% 710K

Health Technology

(0.0% 1d) (-19.4% 1m) (-41.6% 1y) (0.0% 2d) (-1.7% 3d) (-1.9% 7d) (1.18% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 2,041,605,331
http://www.intelliatx.com
Sec Filling | Patents | 270 employees

(US) Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

crispr genomic genome editing glass

add to watch list Paper trade email alert is off